Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Nov;11(11):1543-50.
doi: 10.1517/14712598.2011.616889. Epub 2011 Sep 6.

AE37: a novel T-cell-eliciting vaccine for breast cancer

Alan K Sears  1 , Sonia A Perez, Guy T Clifton, Linda C Benavides, Jeremy D Gates, Kevin S Clive, Jarrod P Holmes, Nathan M Shumway, David C Van Echo, Mark G Carmichael, Sathibalan Ponniah, Constantin N Baxevanis, Elizabeth A Mittendorf, Michael Papamichail, George E Peoples
Affiliations
Review

AE37: a novel T-cell-eliciting vaccine for breast cancer

Alan K Sears et al. Expert Opin Biol Ther. 2011 Nov.

Abstract

Introduction: Immunotherapy, including vaccines targeting the human EGFR2 (HER-2/neu) protein, is an active area of investigation in combatting breast cancer. Several vaccines are currently undergoing clinical trials, most of which are CD8(+) T-cell-eliciting vaccines. AE37 is a promising primarily CD4(+) T-cell-eliciting HER-2/neu breast cancer vaccine currently in clinical trials.

Areas covered: This article reviews preclinical investigations as well as findings from completed and ongoing Phase I and Phase II clinical trials of the AE37 vaccine.

Expert opinion: Clinical trials have shown the AE37 vaccine to be safe and capable of generating peptide-specific, durable immune responses. This has been shown in patients with any level of HER-2/neu expression. Early clinical findings suggest there may be benefit to AE37 vaccination in preventing breast cancer recurrence.

PubMed Disclaimer

Publication types